Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
500 CHF | +194,12 % | -.--% | -.--% |
08.06. | Top-Anwaltskanzleien in US-Opioidklagen erhalten Hunderte von Millionen an Honoraren | RE |
07.06. | Von J&J unterstützte Aktien von Rapport Therapeutics starten fast 6% höher | RE |
Kurzporträt
- Pharmazeutische Produkte (55,4%): Arzneimittel zur Behandlung von Herz-Kreislauf-Erkrankungen, onkologischen Erkrankungen, Magen-Darm-Erkrankungen, infektiösen, immunologischen, neurologischen und dermatologischen Erkrankungen usw.;
- Medizinische Produkte und Geräte (28,9%): Diagnosesysteme, orthopädische und gynäkologische Geräte, chirurgisches Material usw., die von Angehörigen der Gesundheitsberufe verwendet werden;
- Gesundheitsprodukte für Verbraucher (15,7%): OTC-Medikamente (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette und andere Marken), Gesundheits- und Schönheitsprodukte (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena und OGX), Babypflegeprodukte (Johnson's und Aveeno Baby), Mundpflegeprodukte (Listerine), Damenhygieneprodukte (Stayfree und Carefree und o.b.), Wundpflegeprodukte (Band-Aid und Neosporin) usw.
Ende 2022 verfügt Johnson & Johnson über 89 Produktionsstätten in den Vereinigten Staaten (28), Nordamerika (9), Europa (27), Afrika und Asien/Pazifik (25).
Der Nettoumsatz verteilt sich geografisch wie folgt: Vereinigte Staaten (51,2%), Europa (24,7%), Asien/Pazifik und Afrika (17,7%) und Sonstige (6,4%).
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Innovative Medicine
64,3
%
| 52 563 | 55,4 % | 54 759 | 64,3 % | +4,18 % |
MedTech
35,7
%
| 27 427 | 28,9 % | 30 400 | 35,7 % | +10,84 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
54,5
%
| 48 580 | 51,2 % | 46 444 | 54,5 % | -4,40 % |
Europe
24,0
%
| 23 449 | 24,7 % | 20 410 | 24,0 % | -12,96 % |
Asia-Pacific, Africa
16,2
%
| 16 789 | 17,7 % | 13 756 | 16,2 % | -18,07 % |
Western Hemisphere Excluding United States
5,3
%
| 6 125 | 6,5 % | 4 549 | 5,3 % | -25,73 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01.01.89 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 01.01.98 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 05.11.19 |
William Hait
CTO | Chief Tech/Sci/R&D Officer | 74 | 01.01.07 |
Jessica Moore
IRC | Investor Relations Contact | - | 01.11.21 |
Michael Bzdak
PRN | Corporate Officer/Principal | - | - |
Jonathan Sheh
PRN | Corporate Officer/Principal | - | - |
Neil Ackerman
PRN | Corporate Officer/Principal | 47 | 01.01.19 |
Caroline Tillett
PRN | Corporate Officer/Principal | 52 | - |
General Counsel | 53 | 01.01.06 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 25.04.19 |
D. Davis
BRD | Director/Board Member | 72 | 19.06.14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 22.10.09 |
Hubert Joly
BRD | Director/Board Member | 64 | 05.12.19 |
Mark McClellan
BRD | Director/Board Member | 60 | 15.10.13 |
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01.01.89 |
Darius Adamczyk
BRD | Director/Board Member | 58 | 15.02.22 |
Eugene Woods
BRD | Director/Board Member | 59 | 30.11. |
Mark Weinberger
BRD | Director/Board Member | 62 | 05.12.19 |
Nadja West
BRD | Director/Board Member | 63 | 03.12.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 3 119 799 183 | 2 404 640 893 ( 77,08 %) | 713 120 000 ( 22,86 %) | 77,08 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
KENVUE INC. 9,52% | 182 329 550 | 9,52% | 3 518 960 315 $ |
ILLUMINA, INC. 0,51% | 810 170 | 0,51% | 84 484 528 $ |
2 449 183 | 4,18% | 68 944 501 $ | |
NANOBIOTIX 11,93% | 5 623 816 | 11,93% | 39 591 665 $ |
814 586 | 0,45% | 32 591 586 $ | |
MEIRAGTX HOLDINGS PLC 10,33% | 6 641 064 | 10,33% | 32 541 214 $ |
CONTINEUM THERAPEUTICS, INC. 10,42% | 1 979 173 | 10,42% | 30 320 930 $ |
CVRX, INC. 19,00% | 4 103 430 | 19,00% | 28 518 839 $ |
IDORSIA LTD 5,07% | 9 581 882 | 5,07% | 27 551 264 $ |
357 939 | 0,70% | 23 767 150 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Medical Specialties
| |
Pharmaceuticals: Major
| |
AMO Holdings, Inc.
AMO Holdings, Inc. Electronic ComponentsElectronic Technology Part of Johnson & Johnson, AMO Holdings, Inc. is an American company that manufactures surgical medical devices and lens. The company is located in the US. |
Electronic Components
|
Animas LLC
Animas LLC Medical SpecialtiesHealth Technology Animas LLC manufactures and distributes external insulin pumps for diabetes patients. The company was founded on November 5, 1996 and is headquartered in West Chester, PA. |
Medical Specialties
|
Pharmaceuticals: Major
| |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. |
Pharmaceuticals: Major
|
Johnson & Johnson Holdco (NA), Inc.
Johnson & Johnson Holdco (NA), Inc. Household/Personal CareConsumer Non-Durables Johnson & Johnson Consumer, Inc. manufactures health and skin care products. It offers wide variety of lotion, moisturizing cream, baby wash, shampoo and conditioner, baby powder and bath, hand and face wipes, soap, baby oil and cologne. The company was founded on March 8, 2016 and is headquartered in Skillman, NJ. |
Household/Personal Care
|
Janssen-Cilag Ltd.
Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. |
Pharmaceuticals: Major
|
BioMedical Enterprises, Inc.
BioMedical Enterprises, Inc. Medical SpecialtiesHealth Technology BioMedical Enterprises, Inc. designs, manufactures and markets memory metal implants. It offers products: intramedullary fixation which includes hammerLock and hammerSplint and staple fixation which includes speed, step OSStaple and step BOSS. The company was founded by William Casey Fox in 1991 and is headquartered in San Antonio, TX. |
Medical Specialties
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
% 1. Jan. | Kap. | |
---|---|---|
+45,82 % | 765 Mrd. | |
+19,86 % | 331 Mrd. | |
+9,32 % | 299 Mrd. | |
+18,87 % | 248 Mrd. | |
-1,64 % | 219 Mrd. | |
+11,11 % | 216 Mrd. | |
+5,90 % | 164 Mrd. | |
-0,73 % | 162 Mrd. | |
+0,30 % | 123 Mrd. |
- Börse
- Aktien
- 853260 Aktie
- 853260 Aktie
- Unternehmen Johnson & Johnson